

Log of updates to website & data

- Aug 28, 2021 New website live.
- Sep 18, 2021 New data for antibodies & cellular therapies network uploaded.
- Oct 1, 2021 Error in number of trials and participants reporting direct evidence for transfusion related acute lung injury for the comparison convalescent plasma vs. standard care/placebo corrected.
- Oct 2, 2021 Error in reasons for GRADE rating corrected for the following outcomes in antibodies & cellular therapies network: adverse events leading to discontinuation, mechanical ventilation, transfusion-related acute lung injury transfusion-associated circulatory overload, length of hospital stay.
- Oct 12, 2021 Website features upgraded, including: tags to indicate addition of new trials to meta-analysis, social media share buttons, PDF export feature for summary of findings tables, publications page.
- Oct 26, 2021 New trials added to drug treatment network summary of findings tables. Data for summary of effects table forthcoming.
- Nov 1, 2021 The following changes were made:
- GRADE ratings for all indirect and network estimates for drug treatment summary of findings tables updated.
 - Errors in data import in drug treatment summary of findings tables corrected.
- We performed a second NMA to compare the efficacy of different JAK inhibitors. The following nodes were included in the network: baricitinib, ruxolitinib, tofacitinib, corticosteroids + IL6 receptor antagonists, standard care/placebo. Results from this second NMA uploaded. Please select drugs with an asterisk (*) from the drop-down menus to see summary of findings tables.
- Nov 8, 2021 During the previous upload of results for the drug treatments network, GRADE ratings for some indirect comparisons did not appear in the summary of findings tables. This issue affected the following outcomes: mortality, mechanical ventilation, adverse events leading to discontinuation, time to symptom resolution. The issue has now been resolved.
- Jan 20, 2022 New data for drug treatments network uploaded. Please note the following:
- The summary of effects of all available drug treatments compared to standard care is forthcoming
 - Summary of findings tables for molnupiravir and PF-07321332/ritonavir cannot be generated. We have access to unpublished data for both drugs, and cannot publish our findings at this time. Please contact us for more information.
 - The guideline development panel did not consider ICU length of stay, mechanical ventilator-free days, viral clearance, and time to viral clearance critical outcomes for decision-making. Therefore, we did not update the NMA for these outcomes. Data from the last iteration is displayed in the summary of findings tables.

- Jan 21, 2022 Import error in the reasons for rating down the certainty of the evidence corrected for the drug treatment network.
- Jan 24, 2022 New data for the antibodies and cellular therapies network uploaded.
- The following outcomes were updated:
- Non-severe patients only: mortality, mechanical ventilation, admission to hospital, duration of hospitalization, time to symptom resolution
 - Non-severe and critical/severe patients: adverse events leading to discontinuation, infusion reactions
- Mar 4, 2022 Summary of effects of all available drug treatments compared to standard care now updated
- Mar 14, 2022 Data for molnupiravir summary of findings tables uploaded.
Effect estimates for adverse events corrected. Previously not reported per 1,000 patients.
New publications added.
- Mar 22, 2022 Error in spelling of intervention names for drug treatment network corrected.
- Jun 21, 2022 Summary of findings and summary of effects of all prophylactic interventions updated.
- Jan 23, 2023 Updated publications list.
- Feb 16, 2023 Summary of findings for all prophylactic interventions updated. Data now includes updated peer-reviewed data for cilgavimab + tixagevimab vs. standard care/placebo.
- Jun 27, 2023 Spreadsheet for GRADE assessment of NMA is uploaded on the website.
- Aug 28, 2023 Updated prophylaxis publications list.
- Oct 31, 2023 Summary of findings and summary of effects of all non-severe interventions updated.